Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Agilent and Burning Rock announce molecular diagnostics agreement

Agilent and Burning Rock announce molecular diagnostics agreement

30th September 2016

Agilent Technologies has announced a new molecular diagnostics partnership with the Chinese company Burning Rock.

The deal will see Burning Rock – a fast-growing company focused on developing cancer diagnostics derived from DNA sequencing – develop cancer diagnostics in China based on the Agilent SureSelect target enrichment system.

Burning Rock will register its molecular diagnostic kit with the China Food and Drug Administration (CFDA) and believes it will become the first CFDA-approved capture sequencing-based cancer diagnostic assay for the Chinese market.

Fast and accurate cancer diagnoses are of vital importance in China due to its extensive population and growing focus on advancing human health. Target enrichment of the kind offered by Agilent SureSelect saves time and resources by making it possible to focus on regions of interest, rather than looking at the entire genome.

Jacob Thaysen, president of Agilent's diagnostics and genomics group, said: "We believe that target enrichment and next-generation sequencing have a vital role to play in personalising medicine and ultimately delivering treatments tailored to the individual. This is especially so for complex diseases such as cancer."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801826172-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.